1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna starts trial testing Omicron-specific booster shot

01/26/2022 | 05:53pm EDT

Jan 26 (Reuters) - Moderna Inc said on Wednesday it had dosed the first participant in a mid-stage study testing its Omicron-specific booster vaccine candidate.

The company also reported data showing that neutralizing antibodies against the Omicron COVID-19 variant declined 6.3-fold from peak levels six months after a third booster dose of its vaccine but remained detectable. (Reporting by Amruta Khandekar; Editing by Devika Syamnath)


© Reuters 2022
All news about MODERNA, INC.
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17TRANSCRIPT : Moderna, Inc. - Special Call
CI
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 022 M - -
Net income 2022 11 474 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 5,28x
Yield 2022 -
Capitalization 57 031 M 57 031 M -
EV / Sales 2022 1,77x
EV / Sales 2023 3,57x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 143,38 $
Average target price 216,12 $
Spread / Average Target 50,7%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-28.50%37 337
SEAGEN INC.-7.74%26 323
ICON PUBLIC LIMITED COMPANY-30.82%16 524
CELLTRION, INC.-28.79%15 565